Drug Discovery World

JANUARY 9, 2024

However, government initiatives to contain healthcare costs, the sustained high cost of capital and global geopolitical disputes are negatively impacting investor appetites for the sector. The therapy has shown positive results in Phase III trials in both breast and lung cancer.

Drugs 69

Drugs Antibody Gene Editing Medicine 69

Trialfacts

MARCH 1, 2023

If you have been diagnosed with depression and would like to contribute to the development of a potential new treatment, then consider joining this research study! A placebo looks like the study treatment but does not contain the active components. Our key areas of focus are currently hormones, cognition, TMS. Why Participate?

Research 52

Research Clinical Trials Clinical Trials Containment 52

The Pharma Data

AUGUST 30, 2021

New Kisqali ® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2? Health-related quality of life, pain and safety outcomes from phase III VISION trial of investigational radioligand therapy 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. 19, 2:10 PM CEST]. Abstract Title.

HR 52

HR Production Trials Containment 52

Drug Discovery World

APRIL 4, 2023

Read more: New oral option for anaemia of CKD approved in US EA-2353, Endogena Therapeutics The investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) was designated as a Fast Track development programme in February.

FDA Approval 52

FDA Approval In-Vivo Gene Editing Drugs 52

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Essentially, a biologic is a product that is produced from living organisms or that contains components of living organisms.

Development 180

Development Protein Production Hormones 180

The Pharma Data

AUGUST 15, 2021

The approval is based on results from the open-label Study 004 trial (N=61), where the major efficacy endpoint was overall response rate (ORR) in patients with VHL-associated RCC. The WELIREG label contains a boxed warning that exposure to WELIREG during pregnancy can cause embryo-fetal harm. WELIREG is the first HIF-2? of patients.

Hormones 52

Hormones Clinical Trials Clinical Trials Trials 52

Delveinsight

DECEMBER 7, 2020

For instance, the shortage of healthcare professionals can be tackled by creating better diagnostic and treatment procedures, integrating solutions developed by physicians worldwide, and providing them seamlessly over a platform accessed by all practicing physicians. In May 2018, Ava raised about $30 million in a Series B round.

Protein 56

Protein Insulin Hormones FDA Approval 56

The Pharma Data

SEPTEMBER 3, 2020

The research, published in the journal Gut, revealed that 83% of aggressive, metastatic-like tumours contained particularly high levels of a gene called TLR3, part of a damage-alert system that mimics the infection response triggered by viruses, drawing immune cells to the tumour. Source link.

Research 52

Research Genetic Analysis Gene Scientist 52

XTalks

NOVEMBER 9, 2023

XTALKS WEBINAR: The Evolution of the Cardiovascular Clinical Development Landscape and Potential Role of GLP-1 RAs Live and On-Demand: Wednesday, December 6, 2023, at 11am EST (4pm GMT/UK) Register for this free webinar to learn about successful study outcomes in developing GLP1s to new therapeutic areas within cardiovascular medicine and more.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

Olympian Clinical Research

MARCH 3, 2023

When AD develops after your 18th birthday, it is known as adult-onset atopic dermatitis. However, it is possible for adults of all ages to develop eczema. When we are under stress, our bodies release cortisol, a hormone that can weaken the skin’s natural barrier and make it more susceptible to irritation and inflammation.

Clinical Research 52

Clinical Research Production Containment Research 52

The Pharma Data

NOVEMBER 24, 2020

Fast Track Designation is granted to investigational drugs for expedited review by the FDA, to facilitate development of drugs aimed at treating serious or life-threatening conditions and fill unmet medical needs. Eligibility for Accelerated Approval and Priority Review, provided relevant criteria are met·.

Drugs 40

Drugs Clinical Trials Clinical Trials Hormones 40

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Gene 52

Gene Hormones DNA Medicine 52

The Pharma Data

AUGUST 17, 2021

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. by blinded independent central review. with a DoR range of 2.6-35.8+

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

Pfizer

JANUARY 27, 2023

It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives.

Marketing 75

Marketing Production Drugs Licensing 75

The Pharma Data

SEPTEMBER 16, 2020

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

OCTOBER 14, 2020

14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. PLYMOUTH MEETING, Pa. and CHICAGO , Oct.

FDA Approval 52

FDA Approval Hormones Production Drugs 52

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. GLP-1 agonists were first developed as diabetes treatments. percent and 22.5

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

FEBRUARY 8, 2024

Ozempic (Semaglutide) Ozempic sales in 2022: $8.713 billion Company/Developer: Novo Nordisk Date of first FDA approval: December 5, 2017 Indications Ozempic is FDA-approved for: Type 2 diabetes Price of Ozempic: $1,029 for 1.5 Trulicity (Dulaglutide) Trulicity sales in 2022: $7.439 billion Company/Developer: Eli Lilly & Co.

Sales 52

Sales Insulin FDA Approval Drugs 52

Pfizer

AUGUST 15, 2022

It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). Loss of therapeutic effect of PAXLOVID and possible development of viral resistance. FDA Emergency Use Authorization Statement.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

The Pharma Data

FEBRUARY 8, 2021

“The TITAN final analysis data confirm the long-term clinical benefit and consistent safety profile of ERLEADA ® plus ADT without a compromise in health-related quality of life,” said Mary Guckert, RN, MSN, Vice President, Development Leader, Prostate Cancer, Janssen Research & Development, LLC. About ERLEADA ® (apalutamide).

HR 52

HR Hormones Development Production 52

XTalks

MARCH 1, 2021

And while conventional dry eye can have a number of causes — including blepharitis, hormone-related changes in post-menopausal women and contact lens use — mask-associated dry eye is largely cropping up in people who wear face masks for extended periods during the day. But prolonged use of ocular steroids has some serious side effects.

Sales 119

Sales Drugs Life Science Containment 119

The Pharma Data

MARCH 25, 2021

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. SG contains a genotoxic component and can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. About the ASCENT Study. Embryo-Fetal Toxicity.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52

The Pharma Data

APRIL 27, 2021

Today’s ODAC meeting is part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. Roche’s Chief Medical Officer and Head of Global Product Development. “We

Medicine 40

Medicine In-Vitro Antibody Development 40

The Pharma Data

APRIL 23, 2021

The ongoing phase 1 GARNET trial is evaluating dostarlimab as monotherapy in patients with advanced solid tumours. GSK is responsible for the ongoing research, development, commercialisation, and manufacture of each of these products under the Agreement. containing regimen. About GARNET. Indication.

Antibody 52

Antibody Hormones Licensing Licensing 52

Pfizer

DECEMBER 13, 2022

It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). Loss of therapeutic effect of PAXLOVID and possible development of viral resistance . For more information, please visit www.PAXLOVID.com. .

Drugs 110

Drugs Licensing Licensing Production 110

Pharmaceutical Technology

MARCH 2, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

FDA Approval 100

FDA Approval Containment Development Genome 100

XTalks

FEBRUARY 7, 2023

Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. Trodelvy contains a monoclonal antibody linked to the anticancer cytotoxic drug SN-38.

HR 52

HR Hormones FDA Approval Antibody 52

Druggist

NOVEMBER 27, 2020

The approval decision for drug licensing comes from information gathered during clinical trials. The primary evidence comes from the clinical trial involving 1440 patients with acne vulgaris. At the end of the 12-week trial, the treatment was successful in 18.4% and 20.3% (different age groups). What does it mean?

Hormones 98

Hormones Clinical Trials Clinical Trials Containment 98

Pfizer

DECEMBER 20, 2022

Results from these analyses are consistent with previously disclosed efficacy and safety data for the trials. It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death).

Drugs 69

Drugs Licensing Licensing Containment 69

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc. billion.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

JULY 28, 2022

Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and cardiovascular disease.

Biobanking 52

Biobanking Gene Gene Silencing Drugs 52

The Pharma Data

JANUARY 27, 2021

BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. . VANCOUVER, Jan.

In-Vitro 52

In-Vitro Containment Drugs Production 52

Pfizer

NOVEMBER 23, 2022

It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). Loss of therapeutic effect of PAXLOVID and possible development of viral resistance. Our Commitment to Access.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

Roots Analysis

AUGUST 31, 2023

Further, the transcription factors contain two molecular domains, the DNA binding domain and the activation domain. Moreover, some transcription factors contain additional domains, such as ligand binding domain in order to interact with chemical signals.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 10, 2021

By the end of the year, we expect to have five independent TransCon product candidates in clinical development leveraging TransCon technologies through our algorithm for product innovation. Pipeline Updates. •. ?. . . . . •.

Hormones 40

Hormones Clinical Development Clinical Trials Clinical Trials 40

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Development 52